



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C12N 15/12, 15/19, 15/57, 15/62, C07K 16/18, 16/28, 16/24, 16/40, C12Q 1/68, G01N 33/566, 33/68, A61K 38/17, 38/19, 38/48		A2	(11) International Publication Number: WO 00/01817
			(43) International Publication Date: 13 January 2000 (13.01.00)
(21) International Application Number: PCT/US99/12366			
(22) International Filing Date: 6 July 1999 (06.07.99)			
(30) Priority Data:			
09/110,938	6 July 1998 (06.07.98)	US	
09/114,466	13 July 1998 (13.07.98)	US	
60/093,897	23 July 1998 (23.07.98)	US	
09/132,968	12 August 1998 (12.08.98)	US	
09/136,214	18 August 1998 (18.08.98)	US	
60/099,999	11 September 1998 (11.09.98)	US	
(71) Applicant: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).			
(72) Inventors: BATES, Elizabeth, Esther, Mary; 4, place Gabriel Rambaud, F-69001 Lyon (FR). LEBECQUE, Serge, J., E.; 514, Chemin du Marand, F-69380 Civrieux d'Azergues (FR). MURPHY, Erin, E.; 180 Emerson Street, Palo Alto, CA 94301 (US). MATTHEW, Jeanine, D.; 559 Alvarado Street, San Francisco, CA 94114 (US). GORMAN, Daniel, M.; 6371 Central Avenue, Newark, CA 94560 (US). HEDRICK, Joseph, A.; 52-08 Quail Ridge Drive, Plainsboro, NJ 08536 (US). WANG, Luquan; 21 Hollis Road, East Brunswick,			
		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
		Published Without international search report and to be republished upon receipt of that report.	
(54) Title: MAMMALIAN GENES; DENDRITIC CELL PROSTAGLANDIN-LIKE TRANSPONDER (DC-PGT), HDTEA84, HSLJD37R AND RANKL, HCC5 CHEMOKINE, DEUBIQUITINATING 11 AND 12 (DUB11, DUB12), MD-1, MD2 AND CYCLIN E2, RELATED REAGENTS AND METHODS			
(57) Abstract			
<p>Purified genes from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding the polypeptides are provided. Methods of using said reagents and diagnostic kits are also provided. Characterization of genes and products relating to DC-PGT (Dendritic cell prostaglandin-like transporter), HDTEA84, HSLJD37R and RANKL (related to TNF receptor family), HCC5 chemokine, Dub 11 and Dub 12 (Deubiquitinating 11 and 12), MD-1 and MD-2 (proteins which exhibit properties of ligands for proteins exhibiting a leucine-rich protein motif (LRR)) and cyclin E2.</p>			

provides compositions which will be important in the control of cell division and transcription.

SUMMARY OF THE INVENTION

5

The present invention is based, in part, upon the characterization of the genes and products relating to the DC-PGT, HDTEA84, HSLJD37R, RANKL, HCC5 chemokine, Dub11, Dub12, MD-1, MD-2, and cyclin E2. It provides nucleic acids, polypeptides, antibodies, and methods for making and using such compositions.

10

In the DC-PGT embodiments, the invention provides an isolated or recombinant antigenic polypeptide comprising: a plurality of distinct segments, wherein each segment has identity to at least 12 contiguous amino acids from the mature SEQ ID NO: 2; or at least 17 contiguous amino acids from the mature SEQ ID NO: 2. In certain embodiments, the plurality of segments includes one of at least 19 contiguous amino acids; or two of at least 15 contiguous amino acids. Other polypeptides include those wherein the polypeptide: comprises the mature SEQ ID NO: 2; binds with specificity to a polyclonal antibody which specifically binds to SEQ ID NO: 2; or the polypeptide: is a natural allelic variant of SEQ ID NO: 2; is at least 30 amino acids in length; exhibits at least two non-overlapping epitopes specific for SEQ ID NO: 2; is a synthetic polypeptide; is attached to a solid substrate; or is a 5-fold or less conservative substitution from SEQ ID NO: 2. Fusion polypeptides are also provided, e.g., comprising first and second portions, the first portion comprising a sequence as described and the second portion comprising a detectable marker. Pharmaceutical compositions are made available, e.g., comprising a sterile polypeptide, as described, in a pharmaceutically acceptable carrier.

20

25

30

35

Polynucleotide embodiments include an isolated or recombinant polynucleotide encoding a described polypeptide. Preferred forms will be such a polynucleotide which: comprises the mature polypeptide coding portion of SEQ ID NO: 1; or encodes the mature SEQ ID NO: 2. Preferred embodiments include wherein the polynucleotide is: a PCR product; a hybridization probe; a

SUBSTITUTE SHEET (rule 26)

binds to a described polypeptide, comprising: incubating components comprising the compound and the polypeptide under conditions sufficient to allow the components to interact; and measuring the binding of the compound to the polypeptide.

5 In TNF receptor-like embodiments, the invention further provides an isolated or recombinant polynucleotide encoding an antigenic polypeptide comprising at least 17 contiguous amino acids from: the mature polypeptide from SEQ ID NO: 6; the mature polypeptide from SEQ ID NO: 8; the mature polypeptide from SEQ ID NO: 10; the mature polypeptide from SEQ ID NO: 12; the mature polypeptide from SEQ ID NO: 17; the mature polypeptide from SEQ ID NO: 19; the mature polypeptide from SEQ ID NO: 21; or the mature polypeptide from SEQ ID NO: 23. In preferred embodiments, such polynucleotide will encode all of the polypeptide of: signal
10 processed SEQ ID NO: 6; signal processed SEQ ID NO: 8; signal processed SEQ ID NO: 10; signal processed SEQ ID NO: 12; signal processed SEQ ID NO: 17; SEQ ID NO: 19; SEQ ID NO: 21; or SEQ ID NO: 23. Other embodiments include such a polynucleotide, which hybridizes at 55° C, less than 500 mM salt, and 50% formamide to
15 the: mature protein coding portion of SEQ ID NO: 5; signal processed coding portion of SEQ ID NO: 7; signal processed coding portion of SEQ ID NO: 9; signal processed coding portion of SEQ ID NO: 11; mature protein coding portion of SEQ ID NO: 16; polypeptide coding portion of SEQ ID NO: 18; polypeptide coding
20 portion of SEQ ID NO: 20; or polypeptide coding portion of SEQ ID NO: 22. Other forms include those polynucleotides, comprising at least 35 contiguous nucleotides of: mature protein coding portion of SEQ ID NO: 5; signal processed coding portion of SEQ ID NO: 7; signal processed coding portion of SEQ ID NO: 9; signal processed
25 coding portion of SEQ ID NO: 11; mature protein coding portion of SEQ ID NO: 16; polypeptide coding portion of SEQ ID NO: 18; polypeptide coding portion of SEQ ID NO: 20; or polypeptide coding portion of SEQ ID NO: 22. Various expression vectors are provided comprising such a polynucleotide. The invention also provides a
30 host cell containing the expression vector, including a eukaryotic cell.

SUBSTITUTE SHEET (rule 26)

sample is from a human, and the binding compound is an antibody. Such also allow for production of a detection kit comprising the binding compound, and: instructional material for the use of the binding compound for the detection; or a compartment providing segregation of the binding compound.

Polypeptides are also made available, e.g., a substantially pure or isolated antigenic polypeptide, which binds to the described binding composition, and further comprises at least 17 contiguous amino acids from: signal processed SEQ ID NO: 6; signal processed SEQ ID NO: 8; signal processed SEQ ID NO: 10; signal processed SEQ ID NO: 12; signal processed SEQ ID NO: 17; SEQ ID NO: 19; SEQ ID NO: 21; or SEQ ID NO: 23. Preferred polypeptides include those which: comprise at least a fragment of at least 25 contiguous amino acid residues from: a primate HDTEA84 protein; a primate HSLJD37R protein; or a rodent or primate RANKL protein; or are soluble polypeptides; are detectably labeled; are in a sterile composition; are in a buffered composition; bind to an sialic acid residue; are recombinantly produced; or have a naturally occurring polypeptide sequence. In other embodiments, the polypeptide comprises at least 17 contiguous amino acids from the: signal processed SEQ ID NO: 6; signal processed SEQ ID NO: 8; signal processed SEQ ID NO: 12; signal processed SEQ ID NO: 17; SEQ ID NO: 19; SEQ ID NO: 21; or SEQ ID NO: 23.

Methods are provided, including a method of modulating a precursor cell physiology or function comprising a step of contacting the cell with: a binding compound which binds to a described polypeptide; an HDTEA84 polypeptide; an HSLJD37R polypeptide; or a RANKL polypeptide. The method may be one wherein the contacting is in combination with a TNF family ligand, or an antagonist of the TNF family ligand.

In other embodiments, the present invention provides compositions related to other chemokine, Dub, or surface protein genes. Polypeptide embodiments include: a substantially pure or recombinant HCC5 polypeptide exhibiting identity over a length of at least 12 amino acids to SEQ ID NO: 25; an isolated natural sequence HCC5 of mature SEQ ID NO: 25; a fusion protein comprising HCC5 sequence; a substantially pure or recombinant Dub11

SUBSTITUTE SHEET (rule 26)

21. A method of detecting the presence of a complementary polynucleotide in a sample, comprising contacting a polynucleotide of Claim 6 that selectively hybridizes with said complementary polynucleotide in said sample to form a detectable duplex; thereby
5 indicating the presence of said polynucleotide in said sample.

22. A method for identifying a compound that binds to a polypeptide of Claim 1, comprising:

- a) incubating components comprising said compound and said
10 polypeptide under conditions sufficient to allow the components to interact; and
- b) measuring the binding of the compound to said polypeptide.

23. An isolated or recombinant polynucleotide encoding an antigenic polypeptide comprising:

- a) at least 17 contiguous amino acids from the mature polypeptide from SEQ ID NO: 6;
- b) at least 17 contiguous amino acids from the mature
20 polypeptide from SEQ ID NO: 8;
- c) at least 17 contiguous amino acids from the mature polypeptide from SEQ ID NO: 10;
- d) at least 17 contiguous amino acids from the mature polypeptide from SEQ ID NO: 12;
- 25 e) at least 17 contiguous amino acids from the mature polypeptide from SEQ ID NO: 17;
- f) at least 17 contiguous amino acids from the mature polypeptide from SEQ ID NO: 19;
- g) at least 17 contiguous amino acids from the mature
30 polypeptide from SEQ ID NO: 21; or
- h) at least 17 contiguous amino acids from the mature polypeptide from SEQ ID NO: 23.

24. The polynucleotide of Claim 23, encoding all of the polypeptide of:

- a) signal processed SEQ ID NO: 6;
- b) signal processed SEQ ID NO: 8;
- c) signal processed SEQ ID NO: 10;

118

- d) signal processed SEQ ID NO: 12;
- e) signal processed SEQ ID NO: 17;
- f) SEQ ID NO: 19;
- g) SEQ ID NO: 21; or
- h) SEQ ID NO: 23.

5

25. The polynucleotide of Claim 23, which hybridizes at 55° C, less than 500 mM salt, and 50% formamide to the:

- a) mature protein coding portion of SEQ ID NO: 5;
- b) signal processed coding portion of SEQ ID NO: 7;
- c) signal processed coding portion of SEQ ID NO: 9;
- d) signal processed coding portion of SEQ ID NO: 11;
- e) mature protein coding portion of SEQ ID NO: 16;
- f) polypeptide coding portion of SEQ ID NO: 18;
- g) polypeptide coding portion of SEQ ID NO: 20; or
- h) polypeptide coding portion of SEQ ID NO: 22.

10

15

26. The polynucleotide of Claim 25, comprising at least 35 contiguous nucleotides of:

- a) mature protein coding portion of SEQ ID NO: 5;
- b) signal processed coding portion of SEQ ID NO: 7;
- c) signal processed coding portion of SEQ ID NO: 9;
- d) signal processed coding portion of SEQ ID NO: 11;
- e) mature protein coding portion of SEQ ID NO: 16;
- f) polypeptide coding portion of SEQ ID NO: 18;
- g) polypeptide coding portion of SEQ ID NO: 20; or
- h) polypeptide coding portion of SEQ ID NO: 22.

20

25

27. An expression vector comprising the polynucleotide of Claim 23.

30

28. A host cell containing the expression vector of Claim 27, including a eukaryotic cell.

29. A method of making an antigenic polypeptide comprising expressing a recombinant polynucleotide of Claim 23.

35

SUBSTITUTE SHEET (rule 26)

30. A method for detecting a polynucleotide of Claim 23, comprising contacting said polynucleotide with a probe that hybridizes, under stringent conditions, to at least 25 contiguous nucleotides of the:

- a) mature protein coding portion of SEQ ID NO: 5;
- b) signal processed coding portion of SEQ ID NO: 7;
- c) signal processed coding portion of SEQ ID NO: 9;
- d) signal processed coding portion of SEQ ID NO: 11;
- e) mature protein coding portion of SEQ ID NO: 16;
- f) polypeptide coding portion of SEQ ID NO: 18;
- g) polypeptide coding portion of SEQ ID NO: 20; or
- h) polypeptide coding portion of SEQ ID NO: 22;

to form a duplex, wherein detection of said duplex indicates the presence of said polynucleotide.

31. A kit for the detection of a polynucleotide of Claim 23, comprising a compartment containing a probe that hybridizes, under stringent hybridization conditions, to at least 17 contiguous nucleotides of a polynucleotide of Claim b1 to form a duplex.

32. The kit of Claim 31, wherein said probe is detectably labeled.

33. A binding compound comprising an antibody binding site which specifically binds to a polypeptide comprising at least 17 contiguous amino acids from:

- a) signal processed SEQ ID NO: 6;
- b) signal processed SEQ ID NO: 8;
- c) signal processed SEQ ID NO: 10;
- d) signal processed SEQ ID NO: 12;
- e) signal processed SEQ ID NO: 17;
- f) SEQ ID NO: 19;
- g) SEQ ID NO: 21; or
- h) SEQ ID NO: 23.

34. The binding compound of Claim 33, wherein:

- a) said antibody binding site is:

SUBSTITUTE SHEET (rule 26)

- 1) selectively immunoreactive with the:
 - a) signal processed SEQ ID NO: 6;
 - b) signal processed SEQ ID NO: 8;
 - c) signal processed SEQ ID NO: 10;
 - d) signal processed SEQ ID NO: 12;
 - e) signal processed SEQ ID NO: 17;
 - f) SEQ ID NO: 19;
 - g) SEQ ID NO: 21; or
 - h) SEQ ID NO: 23;
- 2) raised against a purified or recombinantly produced human HDTEA84 protein;
- 3) raised against a purified or recombinantly produced human HSLJD37R protein; or
- 4) in a monoclonal antibody, Fab, or F(ab)2; or
- b) said binding compound is:
 - 1) an antibody molecule;
 - 2) a polyclonal antiserum;
 - 3) detectably labeled;
 - 4) sterile; or
 - 5) in a buffered composition.

35. A method using the binding compound of Claim 33, comprising contacting said binding compound with a biological sample comprising an antigen, thereby forming a binding compound:antigen complex.

36. The method of Claim 35, wherein said biological sample is from a human, and wherein said binding compound is an antibody.

37. A detection kit comprising said binding compound of Claim 34, and:

- a) instructional material for the use of said binding compound for said detection; or
- b) a compartment providing segregation of said binding compound.

38. A substantially pure or isolated antigenic polypeptide, which binds to said binding composition of Claim 33, and further comprises at least 17 contiguous amino acids from:

- a) signal processed SEQ ID NO: 6;
- b) signal processed SEQ ID NO: 8;
- c) signal processed SEQ ID NO: 10;
- d) signal processed SEQ ID NO: 12;
- e) signal processed SEQ ID NO: 17;
- f) SEQ ID NO: 19;
- g) SEQ ID NO: 21; or
- h) SEQ ID NO: 23.

39. The polypeptide of Claim 38, which:

- a) comprises at least a fragment of at least 25 contiguous amino acid residues from a primate HDTEA84 protein;
- b) comprises at least a fragment of at least 25 contiguous amino acid residues from a primate HSLJD37R protein;
- c) comprises at least a fragment of at least 25 contiguous amino acid residues from a rodent or primate RANKL protein;
- d) is a soluble polypeptide;
- e) is detectably labeled;
- f) is in a sterile composition;
- g) is in a buffered composition;
- h) binds to an sialic acid residue;
- i) is recombinantly produced, or
- j) has a naturally occurring polypeptide sequence.

40. The polypeptide of Claim 39, which comprises at least 17 contiguous amino acids from the:

- a) signal processed SEQ ID NO: 6;
- b) signal processed SEQ ID NO: 8;
- c) signal processed SEQ ID NO: 10;
- d) signal processed SEQ ID NO: 12;
- e) signal processed SEQ ID NO: 17;
- f) SEQ ID NO: 19;
- g) SEQ ID NO: 21; or
- h) SEQ ID NO: 23.

5	agt tgc atc acc tgt gct gtc atc aat cgt gtt cag aag gtc aac tgc 302 Ser Cys Ile Thr Cys Ala Val Ile Asn Arg Val Gln Lys Val Asn Cys 75 60 65 70
10	aca gct acc tct aat gct gtc tgt ggg gac tgt ttg ccc agg ttc tac 350 Thr Ala Thr Ser Asn Ala Val Cys Gly Asp Cys Leu Pro Arg Phe Tyr 90 80 85
15	cga aag aca cgc att gga ggc ctg cag gac caa gag tgc atc ccg tgc 398 Arg Lys Thr Arg Ile Gly Gly Leu Gln Asp Gln Glu Cys Ile Pro Cys 105 95 100
20	acg aag cag acc ccc acc tct gag gtt caa tgt gcc ttc cag ttg agc 446 Thr Lys Gln Thr Pro Thr Ser Glu Val Gln Cys Ala Phe Gln Leu Ser 110 115 120
25	tta gtg gag gca gat gca ccc aca gtg ccc cct cag gag gcc aca ctt 494 Leu Val Glu Ala Asp Ala Pro Thr Val Pro Pro Gln Glu Ala Thr Leu 125 130 135
30	gtt gca ctg gtg agc agc ctg cta gtg gtg ttt acc ctg gcc ttc ctg 542 Val Ala Leu Val Ser Ser Leu Leu Val Val Phe Thr Leu Ala Phe Leu 140 145 150 155
35	ggg ctc ttc ttc ctc tac tgc aag cag ttc ttc aac aga cat tgc cag 590 Gly Leu Phe Phe Leu Tyr Cys Lys Gln Phe Phe Asn Arg His Cys Gln 160 165 170
40	cgt gga ggt ttg ctg cag ttt gag gct gat aag aca gca aag gag gaa 638 Arg Gly Gly Leu Leu Gln Phe Glu Ala Asp Lys Thr Ala Lys Glu Glu 175 180 185
45	tct ctc ttc ccc gtg cca ccc agc aag gag acc agt gct gag tcc caa 686 Ser Leu Phe Pro Val Pro Pro Ser Lys Glu Thr Ser Ala Glu Ser Gln 190 195 200
50	gtc tct tgg gcc cct ggc agc ctt gcc cag ttg ttc tct ctg gac tct 734 Val Ser Trp Ala Pro Gly Ser Leu Ala Gln Leu Phe Ser Leu Asp Ser 205 210 215
55	gtt cct ata cca caa cag cag cag ggg cct gaa atg tgatgtccac 780 Val Pro Ile Pro Gln Gln Gln Gly Pro Glu Met 220 225 230
60	angagctaata accctacaga tggggcatat cctatcccat cccaccagag gattgattct 840 ccatttcaca aggactgac tggagcattt cttgettccc tgttgtagtc tggggagoca 900 gattccacat tcatgggact accagacatg tt 932
60	<210> 23 <211> 231 <212> PRT <213> Unknown
60	<400> 23 Met Asp Cys Gln Glu Asn Glu Tyr Trp Asp Gln Trp Gly Arg Cys Val 1 5 10 15

SUBSTITUTE SHEET (rule 26)

5	Thr Cys Gln Arg 20	Cys Gly Pro Gly Gln Glu Leu Ser Lys Asp Cys Gly 25 30
	Tyr Gly Glu Gly Gly Asp Ala Tyr Cys Thr Ala Cys Pro Pro Arg Arg 35 40 45	
10	Tyr Lys Ser Ser Trp Gly His His Lys Cys Gln Ser Cys Ile Thr Cys 50 55 60	
15	Ala Val Ile Asn Arg Val Gln Lys Val Asn Cys Thr Ala Thr Ser Asn 65 70 75 80	
	Ala Val Cys Gly Asp Cys Leu Pro Arg Phe Tyr Arg Lys Thr Arg Ile 85 90 95	
20	Gly Gly Leu Gln Asp Gln Glu Cys Ile Pro Cys Thr Lys Gln Thr Pro 100 105 110	
	Thr Ser Glu Val Gln Cys Ala Phe Gln Leu Ser Leu Val Glu Ala Asp 115 120 125	
25	Ala Pro Thr Val Pro Pro Gln Glu Ala Thr Leu Val Ala Leu Val Ser 130 135 140	
30	Ser Leu Leu Val Val Phe Thr Leu Ala Phe Leu Gly Leu Phe Phe Leu 145 150 155 160	
	Tyr Cys Lys Gln Phe Phe Asn Arg His Cys Gln Arg Gly Gly Leu Leu 165 170 175	
35	Gln Phe Glu Ala Asp Lys Thr Ala Lys Glu Glu Ser Leu Phe Pro Val 180 185 190	
	Pro Pro Ser Lys Glu Thr Ser Ala Glu Ser Gln Val Ser Trp Ala Pro 195 200 205	
40	Gly Ser Leu Ala Gln Leu Phe Ser Leu Asp Ser Val Pro Ile Pro Gln 210 215 220	
45	Gln Gln Gln Gly Pro Glu Met 225 230	
	<210> 24	
	<211> 232	
50	<212> DNA	
	<213> Unknown	
	<220>	
	<223> Description of Unknown Organism:primate	
55	<400> 24	
	ttggccttag ggaccaagct tttatcatcg tcagtgggac ttaacctgtc ttaaaagtgc 50	
	tgccttctct acactcgctc aagatcccg gtcagctgta ttatggcatc ctattagtca 120	
60	ggcagcctgt gcttcaagcc cgtagtgtga ttcatccccc aaaggggccca ttccgtttgt 180	
	atcatcacat gtcttcagtg ggtccatgtg tatatcaagg acatgatgca ga 230	

SUBSTITUTE SHEET (rule 26)